Cryptosporidiosis, a widespread diarrheal disease caused by Cryptosporidium (CP) species infection, is an emerging global health problem associated with high morbidity and mortality. The Global Enteric Multicenter Study (GEMS) recently reported this neglected protozoan parasite as 1 of the 4 major diarrheal pathogens worldwide. Although previously known for causing chronic diarrhea in AIDS patients and for major waterborne outbreaks in the Western world, cryptosporidiosis has garnered medical and scientific attention only recently with appreciation of an urgent need to develop effective therapeutic strategies. The current treatment options are severely limited with no vaccines to date and the only FDA approved drug nitazoxanide exhibits limited efficacy. The parasite enters human host via fecal-oral route and infects the host intestinal epithelial cells. A major hurdle in drug development is the poor knowledge of host-parasite interactions primarily due to the lack of a physiologically relevant disease model recapitulating the native human intestinal in vivo environment of the parasite. Animal models are suboptimal for human infection studies, whereas human intestinal transformed cell lines do not truly represent host-parasite interactions in vivo. In this regard, a recent technology to generate human enteroids, small intestinal crypt-derived 3-D organoids with an epithelial layer surrounding a lumen, provided an ex-vivo model truly recapitulating the architecture and functional diversity of the native epithelium. Human enteroids and enteroid-derived polarized monolayers grown on Transwell inserts with distinct apical/basolateral cell surfaces provide exceptional opportunity as physiologically relevant model of human intestine to study host-pathogen interactions. Therefore, we propose the current exploratory studies to establish an ex vivo model of cryptosporidiosis utilizing crypt-derived human enteroids and enteroid-derived monolayers to investigate host-parasite interactions relevant to diarrheal diseases. Diarrhea mainly results from dysregulated intestinal ion and fluid transport (due to decreased absorption and/or increased secretion) and may also involve disruption of intestinal barrier function. Therefore, we hypothesized that a human enteroid model of CP infection will allow, for the first time, characterization of CP-induced dysregulation of epithelial ion transport and barrier function in the human intestine and define novel targets for intervention.
The Specific Aims i nclude: 1) Characterize invasion of C. parvum in human 3-D enteroids/enteroid-derived 2-D monolayers and the effects on epithelial barrier structure and function; 2) Elucidate mechanisms of altered ion transport and luminal fluid accumulation following C. parvum infection of human enteroids/enteroid-derived monolayers. This novel ex-vivo model of cryptosporidiosis should help overcome a major hurdle in studying host-parasite interactions relevant to human infection, identify superior therapeutic targets and establish a highly effective pre-clinical model for high throughput drug screening and thereby forming the basis for a future robust program in drug discovery and development.

Public Health Relevance

Diarrhea caused by infection with the protozoan parasite Cryptosporidium species is becoming increasingly appreciated as a major contributor to diarrheal morbidity and mortality and emerging as a global health problem owing to extremely limited current treatment options. Since the infection involves propagation of the parasite through various life-stages inside the intestinal epithelial cells of human hosts, a major hurdle in developing effective therapeutic strategies is poor understanding of host-parasite interactions due to lack of a suitable disease model. Thus, studies proposed in the current application focus on establishment of a novel model of Cryptosporidium infection utilizing human enteroids (mini intestine) as a pre-clinical model to accelerate identifying effective therapeutic targets against the widespread diarrheal disease caused by this important parasite.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
7R21AI130790-03
Application #
9928699
Study Section
Clinical, Integrative and Molecular Gastroenterology Study Section (CIMG)
Program Officer
Pesce, John T
Project Start
2019-05-22
Project End
2021-04-30
Budget Start
2019-07-01
Budget End
2021-04-30
Support Year
3
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Marshall University
Department
Type
Organized Research Units
DUNS #
036156615
City
Huntington
State
WV
Country
United States
Zip Code
25755